# Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

> **NCT02269176** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 330 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Low dose of telmisartan
- **DRUG:** High dose of telmisartan
- **DRUG:** Low dose of losartan
- **DRUG:** High dose of losartan

## Key facts

- **NCT ID:** NCT02269176
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2001-01
- **Final completion:** —
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2014-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269176, "Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02269176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*